Skip to main content

Table 2 Univariate analysis

From: A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy

 

BF

DM

PCSM

OM

PSADT < 6 months

HR: 2.3

HR: 2.8

HR: 3.3

HR: 1.80

[95%CI: 1.6-3.3]

[95%CI: 1.7-4.6]

[95%CI: 1.6-6.9]

[95%CI: 1.1-3.0]

p<0.0001

p<0.0001

p=0.0007

p=0.01

Pre-SRT PSA

HR: 1.2

HR: 1.2

HR: 1.2

HR: 1.2

[95%CI: 1.1-1.3]

[95%CI: 1.1-1.3]

[95%CI: 1.1-1.3]

[95%CI: 1.01-1.2]

p<0.0001

p<0.0001

p<0.0001

p=0.0003

ADT during SRT

HR: 0.8

HR: 0.9

HR: 0.9

HR: 1.1

[95%CI: 0.5-1.2]

[95%CI: 0.46-1.77]

[95%CI: 0.3-2.4]

[95%CI: 0.6-2.3]

p=0.3

p=0.8

p=0.8

p=0.7

Gleason score*

HR: 1.5

HR: 1.8

HR: 2.0

HR: 1.2

[95%CI: 1.2-1.7]

[95%CI: 1.4-2.4]

[95%CI: 1.4-2.9]

[95%CI: 0.9-1.5]

p<0.0001

p<0.0001

p=0.0002

p=0.18

SVI

HR: 2.2

HR: 2.3

HR: 3.2

HR: 2.2

[95%CI: 1.3-3.7]

[95%CI: 1.1-4.9]

[95%CI: 1.1-9.9]

[95%CI: 1.0-4.7]

p=0.0001

p=0.0034

p=0.002

p=0.008

ECE

HR: 1.8

HR: 1.5

HR: 1.7

HR: 1.6

[95%CI: 1.3-2.5]

[95%CI: 0.9-2.4]

[95%CI: 0.8-3.4]

[95%CI: 0.97-2.6]

p=0.0004

p=0.12

p=0.16

p=0.07

SM

HR: 0.6

HR: 0.7

HR: 1.2

HR: 0.9

[95%CI: 0.5-0.9]

[95%CI: 0.5-1.2]

[95%CI: 0.6-2.4]

[95%CI: 0.5-1.4]

p=0.005

p=0.3

p=0.7

p=0.5

LNI

HR: 1.2

HR: 2.0

HR: 3.6

HR: 1.9

[95%CI: 0.4-4.3]

[95%CI: 0.3-14.1]

[95%CI: 0.3-47.7]

[95%CI: 0.3-12.9]

 

p=0.7

p=0.3

p=0.06

p=0.4

  1. Abbreviations: BF; Biochemical failure, DM; Distant metastasis, PCSM; Prostate cancer-specific survival, OM; Overall mortality, PSADT; Prostate-specific antigen doubling time, PSA; Prostate-specific antigen, SRT; Salvage radiation therapy, SVI; Seminal vesicle invasion, ECE; Extra-capsular extension, SM; Surgical margin, LNI; Lymph node involvement, HR; Hazard ratio, CI; Confidence interval, *Cox-proportional hazards.